Navigation Links
Indevus Pharmaceuticals To Present at RBC Capital Markets Conference
Date:12/5/2007

mpany's filings under the Securities Act of 1933 and the Securities Exchange Act of 1934 under "Risk Factors" and elsewhere, and include, but are not limited to: dependence on the success of SANCTURA(R), SANCTURA(R) XR, NEBIDO(R) , VANTAS(R) and SUPPRELIN(R) LA; the early state of products under development; uncertainties relating to clinical trials, regulatory approval and commercialization of our products, particularly SANCTURA XR, NEBIDO, and VALSTAR(TM); risks associated with contractual agreements, particularly for the manufacture and co-promotion of SANCTURA and SANCTURA XR and the manufacture of NEBIDO, VANTAS, SUPPRELIN LA and VALSTAR; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; competition; need for additional funds and corporate partners, including for the development of our products; failure to acquire and develop additional product candidates; changes in reimbursement policies and/or rates for SANCTURA, VANTAS, SUPPRELIN LA, DELATESTRYL(R) and any future products; history of operating losses and expectation of future losses; product liability and insurance uncertainties; risks relating to the Redux- related litigation; the risk that the businesses of Indevus and Valera Pharmaceuticals, Inc. will not be integrated successfully during the period following the related merger; the risk that the cost savings and any other synergies from the merger may not be fully realized or may take longer to realize than expected; market acceptance for the merger and approved products; risks of regulatory review and clinical trials; disruption from the transaction making it more difficult to maintain relationships with customers, employees or suppliers; competition and its effect on pricing, spending, third-party relationships and revenues; reliance on intellectual property and having limited patents and proprietary rights; dependence on market exclusivity, valuation of our Common Stock; risks related
'/>"/>
SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Indevus Pharmaceuticals to Present at Upcoming Investor Conferences
2. FDA Accepts New Drug Application for NEBIDO(R) Submitted by Indevus
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
6. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
7. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
9. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
11. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... ... 2015 , ... An article published August 19th by the LA ... through to open a pizzeria in Westchester. Mr. LaRocco was aware from opening prior ... but the current process, having already gone on for over a year, is taking ...
(Date:8/28/2015)... ... August 28, 2015 , ... For Dallas, the time is nearing for the ... USPI Tenet Health. , The American Heart Association hosts their well-known Heart Walk to ... that together, a difference can be made. Walkers can participate in the cause and ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... As ... from Merz, received FDA clearance for results that last for two years, the ... exciting news for patients who are looking for a long-lasting, effective solution for their ...
(Date:8/28/2015)... ... August 28, 2015 , ... On May 30th, 2015, Best Drug Rehabilitation, ... the “Music With A Mission” benefit concert in Mendon, IL. Held in the Show ... money to support music education programs in the underfunded local school districts of Mendon ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... grams of high grade protein with zero fat, carbs, sugar, gluten, lactose or ... named a finalist for the 2015 SupplySide CPG Editor’s Choice Awards. , Five ...
Breaking Medicine News(10 mins):Health News:Article on Building Approval Process for LA Business Highlights the Need for a Bridge Between Businesses and City Officials, says Fire Protection Group Inc. 2Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:New Video Released on "Music With A Mission" Benefit Concert Headlining Artist Cadillac Three & Best Drug Rehabilitation 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3
... 10 U.S. adults suffer chronic pain that lasts a year or ... a record average of just short of 80 years, according to ... Disease Control and Prevention. ,The CDC said, 'At birth, ... 75 for males. The gap in life expectancy between white and ...
... of influenza viruses found in birds with the avian virus ... to researchers indicating pandemic strains// of bird flu. ... of the journal Nature which illustrates the genetic changes required ... enough to recognize the receptors on human cells. ...
... Alpha-1-antitrypsin deficiency, a genetic disorder, know that they shouldn't ... increased risk for// developing emphysema at a young age. ... patients with alpha-1-antitrypsin (AT) deficiency could develop serious liver ... (NSAIDs). ,A new research performed at Washington ...
... them alleviate symptoms like forgetting, distracted, impulsive or fidgety ... University Medical Center// investigates whether these symptoms of Attention ... ,If that is the case, will ... help people quit smoking – the patch with counseling ...
... childcare worker should be trained in how to handle ... today.// ,'The AMA is calling on all State ... for people who work with children,' Dr Haikerwal said. ... for anaphylactic shock, including how to use auto-injecting devices ...
... Court was notified on Wednesday by the State government ... fake doctors //in the State of Maharashtra. ,Following ... against a fraudulent doctor by a Govandi resident, Mariappa ... while under the treatment of an unqualified bogus doctor. ...
Cached Medicine News:Health News:Scinetists Alert to Onset of Pandemic through Bird flu Mutations to Humans 2Health News:Non-Steroidal Anti-Inflammatory Drugs Can Cause Liver Damages 2Health News:Non-Steroidal Anti-Inflammatory Drugs Can Cause Liver Damages 3Health News:A New Study To Examine ADHD's Role In Smoking 2
(Date:8/28/2015)... Aug. 28, 2015 ... addition of the "Investigation Report on China,s ... offering. Developed by Novo Nordisk, insulin ... an important drug for the treatment of diabetes. ... fast- acting insulin analog, starts working fast and ...
(Date:8/28/2015)... , Aug. 28, 2015 Perrigo Company plc ... the Mylan N.V. ("Mylan") (NASDAQ: MYL ) shareholder ... "Our views of Mylan,s offer to Perrigo ... based on our Board,s careful reflection of the value ... the limited choices that Mylan has allowed its shareholders ...
(Date:8/28/2015)... The report "Eubiotics Market by Type (Probiotics, Prebiotics, Organic Acids, ... by Region ( North America , ... of the World) - Global Trends and Forecast to 2020", ... at USD 4.62 Billion in 2014 and is projected to ... 7.4% from 2015 to 2020. Browse 77 ...
Breaking Medicine Technology:China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5
... , , INDIANAPOLIS, July 22 ... during a lease signing event that it has become the first ... Technology at East River Science Park, a development that shows tangible ... for biopharmaceutical research. The biotech park -- located adjacent to the ...
... , , MENLO PARK, Calif., ... BlueShield has adopted a positive coverage policy for the measurement ... determined that the published, peer-reviewed evidence is sufficient to support ... July 20, 2009, states the measurement of exhaled nitric oxide ...
Cached Medicine Technology:Lilly and New York City Mayor Michael R. Bloomberg Announce Lilly Agrees to be First Tenant of East River Science Park; Issue Urgent Call for Healthcare Reform that Protects Innovation and Jobs 2Lilly and New York City Mayor Michael R. Bloomberg Announce Lilly Agrees to be First Tenant of East River Science Park; Issue Urgent Call for Healthcare Reform that Protects Innovation and Jobs 3Lilly and New York City Mayor Michael R. Bloomberg Announce Lilly Agrees to be First Tenant of East River Science Park; Issue Urgent Call for Healthcare Reform that Protects Innovation and Jobs 4Lilly and New York City Mayor Michael R. Bloomberg Announce Lilly Agrees to be First Tenant of East River Science Park; Issue Urgent Call for Healthcare Reform that Protects Innovation and Jobs 5CareFirst BCBS Covers eNO Measurement for Diagnosis, Asthma Treatment 2
... The Model 130 has expanded memory capabilities ... has memory to retain oxygen saturation and pulse ... modes to best suit your needs:, ,1. ... minutes of information for a single patient, making ...
... Oximeter provides SpO 2 and pulse rate ... The device is battery or AC powered, has ... audible alarm signals, and an infrared link to ... is also available for added protection. The ...
... The FingerPrint Pulse Oximeter is ... with an integral printer. A ... 2 and pulse rate measurements, ... on 4 AA alkaline batteries, and ...
... oximetry monitoring system compatible with personal ... Extremely rugged and cost-effective.The BCI 3301 ... delivers pulse oximetry wherever spot-checking is ... clinics and hospitals. In fact, its ...
Medicine Products: